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Summary
Rationale—Effective treatment for drug susceptible tuberculosis rapidly renders patients non-
infectious – long before sputum acid-fast smear or culture conversion to negative. Multidrug-
resistant tuberculosis (MDR-TB) patients on treatment are currently assumed to remain infectious 
for months. While the resources required for prolonged hospitalization are a barrier to MDR-TB 
treatment scale-up, the safety of community treatment is clear.
Objectives—To estimate the impact of effect treatment on MDR-TB patient infectiousness.
Methods—A series of five human-to-guinea pig tuberculosis transmission studies tested various 
infection control interventions. Exhaust air from a hospital ward occupied by mostly sputum 
smear and culture positive MDR-TB patients exposed guinea pigs in adjacent chambers. Guinea 
pigs were tuberculin skin tested for infection. Only the control groups of guinea pigs from each 
study (no interventions used) provide the data for this analysis.
Measurements—The number of guinea pigs infected in each study is reported and correlated 
with M. tuberculosis drug susceptibility relative to treatment.
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Main Results—Despite exposure to presumably infectious MDR-TB patients, guinea pig 
infection percentages ranged from 1 to 77% among the 5 experiments. In one experiment, in 
which 27 MDR-TB patients newly started on effective treatment exposed guinea pigs for 3 
months, there was minimal transmission. In 4 other experiments with greater transmission, guinea 
pigs had been exposed to patients with unsuspected extensively drug resistant tuberculosis (XDR-
TB) - not on effective treatment.
Conclusions—In this model, effective treatment appears to render MDR-TB patients rapidly 
non-infectious. Further prospective studies on this subject are needed.
Keywords
multidrug resistant tuberculosis; impact of treatment; transmission; extensively drug resistant 
tuberculosis
Introduction
WHO estimates that up to five hundred thousand new multidrug resistant tuberculosis 
(MDR-TB) cases occur each year. More than half occur in previously untreated persons—
the result of transmission—and in many cases, re-infection1. There is considerable evidence 
that a substantial portion of tuberculosis transmission occurs in hospitals and other 
congregate settings2–4. Globally, most MDR-TB cases are treated in hospitals for at least the 
first 6 months while receiving injectable drugs5,6. They remain hospitalized until smear or 
culture conversion, the benchmark by which MDR-TB patients are generally considered 
non-infectious. However, in many high burden settings for MDR-TB, such as South Africa, 
there is a growing gap between the need for MDR-TB treatment and the availability of 
hospital beds, resulting in waiting periods for patients to begin therapy7. Moreover, the gap 
is increasing with the implementation of rapid molecular diagnostics testing for drug 
resistance8. In response, South Africa is implementing community-based treatment, as 
already practiced in many sites around the world7,9. Globally, however, enthusiasm for 
community-based treatment is dampened by concern about potential transmission before 
sputum smear and culture conversion10,11.
Exactly how long MDR-TB patients remain infectious after the initiation of effective 
therapy is unclear. A 2008 task force of the US CDC Advisory Committee for the 
Elimination of Tuberculosis (ACET) reviewed the medical and public health literature and 
found little or no evidence in support of any particular policy12. For drug susceptible TB, 
however, policies from 5 public health sources indicated that isolation can be discontinued 
after two weeks of effective treatment, some specifying with and some without sputum 
smear or culture conversion. During the 1985–1992 resurgence of TB in the United States, 
nosocomial transmission of MDR-TB to other patients and health care workers was 
attributed largely to patients who were released from respiratory isolation after two weeks of 
ineffective therapy for presumed drug susceptible TB13. In response to what was at that time 
considered a critical policy failure, the two week rule was dismissed as not applicable to 
drug resistant TB14. Lacking specific data on the impact of effective treatment on MDR-TB, 
programs have commonly recommended respiratory isolation and/or separation of MDR-TB 
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patients on treatment until smear or culture conversion, which usually occurs after 2 to 6 
months.
Here we present preliminary observations – obtained retrospectively from a series of 5 
experiments conducted for other purposes – and discuss how our data, like previously 
published epidemiological and experimental observations for drug susceptible TB, show that 
MDR-TB transmission is rapidly reduced following the initiation of effective treatment – 
well before sputum smear and conversion.
Methods
This report consists of a descriptive re-analysis of the tuberculin skin test (TST) conversions 
among guinea pigs exposed in 5 separate human-to-guinea pig transmission experiments 
conducted to test infection control interventions. However, only conversions for animals in 
the control (non-intervention) chambers are used for this analysis.
The 5 experiments were conducted at the Airborne Infections Research (AIR) Facility in 
Mpumalanga Province, South Africa. The AIR facility consists of three, 2-bed patient 
rooms, corridor, common room, and ablution facilities, most of the air from which is 
exhausted through two large guinea pig exposure chambers in a separate, adjacent part of the 
building. Patients with documented MDR-TB admitted to the adjacent Mpumalanga 
Provincial MDR-TB Treatment Center to begin or continue standardized treatment were 
recruited, with informed consent, to participate in the study as human sources of contagion 
for the guinea pigs. The South African Ministry of Health standardized MDR-TB treatment 
regimen consisted of levofloxacin, kanamycin, ethionamide and either ethambutol or 
prothionamide, depending on in vitro susceptibility to ethambutol. Consent included 
agreement to spend at least 20 hours per day inside the AIR facility. AIR facility patients 
received exactly the same treatment as patients on the main MDR-TB wards from which 
they were recruited.
The AIR facility was designed to test airborne infection control interventions, such as 
germicidal ultraviolet air disinfection, surgical masks on patients, and mechanical room air 
(filtration) cleaners15. In those experiments, air from the patient rooms and corridor was 
exhausted to one guinea pig exposure chamber on odd calendar days when the intervention 
was in use and to identical control guinea pig exposure chambers on even calendar days 
when no intervention was in use. The difference in guinea pig infections was a direct 
measure of the efficacy of the interventions tested. Importantly, the guinea pig infections 
included in this current analysis are from the control guinea pig exposure chambers only. TB 
transmission to the control guinea pigs was therefore not influenced by the interventions 
being tested. In the pilot study only, organs/tissues from guinea pigs that developed active 
TB were frozen and subsequently cultured for M. tuberculosis using solid agar culture 
methods. M. tuberculosis isolates from the guinea pig tissues were further characterized by 
drug susceptibility testing (DST) in liquid media and by spoligotyping for linkage with 
human source case isolates on the ward at the time. (15) In the four other experiments, 
culturing of guinea pigs was not performed. The details of animal care, tuberculin skin 
testing, microbiology, and genetic fingerprinting have been published15.
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In all 5 experiments, enrolled subjects served primarily as sources of infectious droplet 
nuclei. Inclusion criteria were: 1) newly diagnosed MDR-TB referred to the provincial 
treatment center to begin or continue chemotherapy, 2) sputum smear positive status, 3) 
chronic cough, and 4) lung cavitation on chest radiograph. Not all inclusion criteria were 
required or present for each subject. Exclusion criteria included clinical conditions judged 
by the hospital physician to be pre-terminal or too poor for study participation. New subjects 
were recruited to replace existing subjects approximately every two to three weeks. In some 
experiments chronic patients on therapy who remained smear positive and coughing were 
admitted to the AIR facility to populate the ward with subjects likely to be infectious.
Patient bacteriology
Referrals to the MDR treatment center are based on South African National Reference 
Laboratory reports of MDR-TB from referring clinics or general hospitals, usually within 
the preceding 2 months. Following admission to the AIR facility, sputum samples were 
obtained three times per week for AFB smear, liquid culture, and DST by MGIT liquid 
culture. All M. tuberculosis isolates recovered after study entry were frozen for possible 
future analyses, including second-line DST and genotyping – procedures not included in our 
transmission intervention testing protocols. Second-line DST was performed using the 
MGIT and line-probe methodologies by the Medical Research Council16, which is a supra-
national reference laboratory for TB.
The human studies protocols were approved by the ethics committees of the South African 
Medical Research Council, CDC, Harvard School of Public Health, and Brigham and 
Women’s Hospital. Animal use committees approved the protocols from the South African 
Medical Research Council, CDC, and Harvard Medical School.
Results
Subject characteristics
Demographic and clinical characteristics of subjects occupying the AIR facility in each 
study are shown in Table 1. All patients enrolled in the studies had chronic cough, and the 
large majority of patients in all study (exact proportion not shown) were smear positive at 
entry. Studies were conducted from 2005 to 2010.
Treatment initiation
Patients were routinely started on MDR-TB therapy after a brief initial evaluation, including 
the collection of sputum for culture and DST. In practice, treatment usually began either on 
the day of admission or the next day. On average, 76% percent of the MDR-TB patients 
admitted to the AIR facility had less than 24 hours of treatment (Table 1). As previously 
noted, occasional patients admitted to the AIR facility had been on therapy for weeks or 
months, but had remained smear positive and coughing. These patients greatly skew the 
mean and median duration of therapy and, in retrospect, some had XDR TB isolates, an 
important finding in this analysis.
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Although bacteriological evidence of MDR-TB is required for referral of patients to the 
Mpumalanga MDR-TB Treatment Center, repeat cultures in the hospital were sometimes 
negative. This phenomenon, along with contamination of stored specimens, accounts for 
incomplete patient microbiological data for some patients in several experiments.
Table 4 indicates the prevalence of XDR-TB among patient isolates available for full DST. 
Experiment 3 had the highest number of isolates available for drug susceptible testing. No 
XDR isolates were identified in that patient cohort, and this was subsequently confirmed by 
line probe assay.
Transmission
Despite consistent recruitment of presumably highly infectious patients into the AIR facility, 
there was marked experiment to experiment variation in the proportion of TST conversions 
among the exposed (control chamber only) guinea pigs (Table 2). In experiment 3, only 1 
guinea pig infection occurred after 3 months exposure to 27 patients. All other experiments 
had 2 to 5 patients with XDR-TB and were associated with greater transmission.
Discussion
We performed a secondary analysis of guinea pigs exposed to patients with MDR-TB in 
experimental studies designed to investigate interventions to reduce airborne transmission. 
Our preliminary data suggest that the standard MDR treatment regimen in South Africa 
rapidly and effectively inhibited transmission. Our observations are consistent with the 
epidemiological and experimental evidence gathered over 60 years for drug susceptible TB 
showing that effective treatment is the dominant factor determining transmission cessation.
Epidemiological studies
The duration of infectiousness of tuberculosis patients started on therapy became a critical 
question soon after the introduction of effective drug regimens in the 1950s. As early as 
1962, Crofton, reflecting on the prospective, randomized clinical trial of ambulatory 
treatment in Madras (now Chennai), India, suggested that hospitalization was probably not 
necessary for the prevention of further transmission17,18. In that study, home treatment from 
the beginning (with only INH and PAS) resulted in no more household infections or cases 
among household contacts than the same treatment given entirely in the hospital for an 
entire year17.
Several other studies conducted in the United States support the consistent observation that 
patients on effective therapy were not infectious for previously uninfected household 
contacts regardless of positive sputum smear and culture status. In 1973, Brooks and 
colleagues reported the absence of TST conversions among 107 TST negative household 
contacts of 21 patients with tuberculosis sent home after up to 23 days hospitalization19. 
Nineteen of those 21 patients were still sputum smear positive when they were sent home, 
and some did not convert their sputum smear to negative until after 5 months treatment. In 
1974, Gunnels and colleagues reported the infection rate among 500 household contacts of 
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155 TB patients sent home after 1 month of treatment20. There was no difference in the 
infection rate among 284 household contacts of 86 culture positive cases (52 of them smear 
and culture positive) compared to 216 household contacts of 69 culture negative cases.
In a comprehensive 1976 analysis of tuberculosis transmission factors and the impact of 
chemotherapy, Rouillon and colleagues reviewed these and other epidemiological studies of 
TST conversions among the household contacts and concluded:
“There is an ever-increasing amount of evidence in support of the idea that 
abolition of the patient’s infectiousness – a different matter from ‘cure,’ which 
takes months, and from negative results of bacteriological examinations, direct and 
culture, which may take weeks – is very probably obtained after less than 2 weeks 
of treatment”21.
This appears to be the first reference to what has become the “two week rule”. Its wide 
adoption in most infection control guidelines implicitly acknowledges the discordance of 
sputum smear and culture status and infectiousness of patients on therapy. Despite the rapid 
bactericidal effects of INH and rifampin-containing regimens, sputum smear and culture 
conversion uncommonly occurs by two weeks. The mean number of days before the first of 
three consecutive negative sputum smears has been reported as 33 days, and the median, 23 
days22.
In a critical review of the impact of chemotherapy on transmission, Menzies urged caution 
in accepting the conclusions of the Madras study, the only prospective, randomized clinical 
trial data, because of high rates of transmission in the community that could have obscured a 
difference in household transmission between home and hospital treatment23. Because the 
other household contact observations were not randomized trials, he pointed out the 
potential for bias if less sick and less infectious patients were sent home on treatment. He 
did not comment on the Gunnels study where both sputum smear and culture positive and 
negative patients were sent home. He further argued that uninfected household contacts at 
the time of diagnosis of the index case may represent individuals with greater innate or 
adaptive immunity to TB infection, and that most uninfected household contacts and health 
care workers today in low-burden settings are likely to be more vulnerable to infection than 
in the past. Implicit in his review of the literature is the common assumption that sputum 
smear or culture positive patients on therapy remain infectious. The same assumption is the 
basis for a recent report from Peru showing that 10% of successfully treated drug susceptible 
patients on chemotherapy remained culture positive at 60 days and, according to the authors, 
should be considered still infectious24. Menzies concluded that there was no credible 
evidence that sputum culture positive TB patients on therapy are not infectious23. While 
Riley’s natural human-to-guinea pig studies (see below for further discussion of these) were 
cited in both the Menzies and Fitzwater papers, there was no mention that the profound 
impact on transmission was due to treatment started on the same day that the patients 
entered the experimental ward, long before sputum smear or culture conversion23–25.
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In their first two year human-to-guinea pig transmission study, for the initial several months, 
Riley and colleagues observed 3 to 4 guinea pig infections per month from exposure to 
smear positive, chronic, previously treated TB patients26. However, for the following 4 
month period, despite continued admission of smear positive patients, guinea pig infections 
stopped completely. This dramatic change in transmission corresponded to a change to 
recruiting new, previously untreated subjects. When chronic, previously treated TB patients 
were again admitted to the ward, transmission to guinea pigs resumed at previous rates, 
suggesting that effective treatment, started on the day of admission, had rapidly and 
profoundly interrupted transmission26.
Recognizing the powerful impact of treatment on transmission, during his second 2-year 
study Riley exposed guinea pigs for periods to untreated as well as treated patients25. The 
result was a direct comparison of the relative effects of treatment on the infectiousness of 
patients with drug susceptible and drug resistant TB (Table 3). Note that there was no MDR-
TB at that time since this was many years before the introduction of rifampin. The rapid 
effect of treatment on transmission was accomplished with just INH, PAS, and 
streptomycin25. As in the first study, treated patients were started on the same day that they 
were admitted to the ward – not two weeks or even two days before admission. The 98% 
reduction in infectiousness reported represented very little treatment with drug regimens far 
less effective than those used today. Some drug resistant cases also responded to treatment 
with the remaining effective drugs, but the numbers of such human subjects and guinea pig 
infections was too small for firm conclusions25. Riley concluded: “The treated patients were 
admitted to the ward at the time treatment was initiated and were generally removed before 
the sputum became completely negative. Hence the decrease in infectiousness preceded the 
elimination of the organisms from the sputum, indicating that the effect was prompt as well 
as striking.” Regarding drug resistant TB, he was more cautious because of the smaller 
numbers, concluding only that “Drug therapy appeared to be effective in reducing the 
infectivity of patients with drug resistant organisms, but the data do not permit detailed 
analysis of the problem”23.
In another similar, more recent study of the infectivity of TB/HIV patients using the human-
to-guinea pig natural transmission model in Lima, Peru, Escombe observed that virtually all 
transmission was from inadequately treated drug resistant strains27. In that study, 97 HIV+ 
pulmonary TB patients exposed 292 guinea pigs over 505 days. Of these patients, 66 were 
culture positive and 35 were sputum smear positive. Of 125 infected guinea pigs, 122 (98%) 
were infected with strains genetically linked to 9 MDR patients who were inadequately 
treated or where treatment was delayed. Three drug susceptible patients infected one guinea 
pig each – two had had delayed treatment and one had had treatment stopped for side 
effects. These data are consistent with both Riley’s results and ours, suggesting transmission 
almost exclusively from patients on ineffective treatment. In Escombe’s study approximately 
66% of patients with drug susceptible strains had been on 2 weeks or more of treatment at 
the time of admission (personal communication, R. Escombe, 2013). However, the 34% of 
drug susceptible TB patients treated less than 2 weeks, representing patients more likely to 
be infectious, failed to transmit their infection on treatment, except as noted above.
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In our studies, in response to the surprising drop in infection rate observed between our pilot 
study and Experiment 1 (74% to 10%), we examined all available chest radiographs and 
concluded that the patients appeared to have similar disease severity and cavitation. Sputum 
smear score averaged 1.5 to 3 out of 3 in all 5 experiments. The same Hartley strain of 
guinea pigs had been obtained from the same breeder, and the skin testing reagents and 
procedures were identical. A probable explanation for the variable infection rates became 
apparent only retrospectively when the results were available for the drug susceptibility tests 
and spoligotypes from the stored pilot study isolates from both patients and guinea pigs. As 
we noted in the published report of our pilot study28, all 13 available guinea pig isolates 
matched two strains from patients, which we retrospectively identified as XDR-TB. 
Subsequently, available isolates from the remaining experiments were sent for second-line 
DST, revealing that 4 of the 5 experiments with substantial transmission to guinea pigs had 
patients with unsuspected XDR-TB. Experiment 3, in which only 1 guinea pig was infected 
by 27 patients over 3 months, failed to have XDR-TB in any of 21 patient isolates available 
for second line DST.
Our preliminary data suggest that the standard MDR treatment regimen in South Africa 
rapidly and effectively inhibited transmission. Our observations are consistent with the 
epidemiological and experimental evidence gathered over 60 years for drug susceptible TB 
showing that effective treatment is the dominant factor determining transmission. The 
epidemiological literature suggests that only 1 in 3 smear positive tuberculosis patients, on 
average, infect their close contacts29,30. In cough aerosol sampling studies, Mtb was cultured 
from only approximately 1 in 3 smear positive patients31. Both human sources and 
mycobacterial strains vary in infectiousness32. Strikingly, however, the absence of XDR-TB 
isolates in Experiment 3 was associated with the near absence of transmission to guinea 
pigs, despite 3 months exposure to 27 sputum positive MDR-TB patients selected for 
probable infectiousness.
The mechanism by which effective chemotherapy rapidly reduces TB transmission is 
unknown. Loudon and colleagues theorized that as respiratory droplets evaporate into 
droplet nuclei, drug concentrations surrounding airborne organisms must increase 
dramatically, possibly inactivating organisms and blocking successful implantation in 
hosts33. However, experiments with aerosolized M. tuberculosis exposed to sub-lethal 
concentrations of INH still grew on settling plates and failed to support that argument, at 
least as far as culture was concerned33. However, in considering the discordance of aerosol 
infectivity and sputum culturability it should be noted that organisms in culture do not 
undergo the stresses of aerosolization or drug exposure, and that growth is supported under 
optimal culture conditions, whereas inhaled organisms face innate and adaptive host 
defenses. More intriguing are recent observations that M. tuberculosis can rapidly undergo 
massive transcriptional responses to moderate stresses without an effect on growth or 
survival34. It is plausible that rapid transcriptional responses to antimycobacterial drugs 
could impact virulence or tolerance to aerosolization without impacting growth in culture.
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This is a retrospective re-analysis of data collected for transmission intervention studies. 
Clinical and microbiological data are incomplete, and we lacked second line drug 
susceptibility information on all patients entering the AIR Facility. Only recently has 
second-line DST become routinely available for MDR-TB patients failing the standard 
South African treatment regimen. Therefore, the diagnosis of extensively drug resistant TB 
(XDR-TB) was not available at the time of patient recruitment into our studies and could not 
have influenced their treatment during their stays in the AIR facility. Recovery of isolates 
from the guinea pigs was also limited. Nevertheless, we present observations that suggest 
that transmission occurred largely from patient cohorts that included unsuspected XDR-TB 
patients receiving standardized MDR-TB treatment, and that in the single cohort 
(experiment 3) in which we identified no XDR, there was nearly no transmission. We 
recognize that TB cases are inherently variable in infectiousness and that chance could 
account for these results, but our results are consistent with a large number of 
epidemiological and two other guinea pig studies that clearly demonstrate the predominant 
impact of treatment on transmission.
Conclusion
Airborne transmission may be the weak link in TB propagation, and it is likely that very 
little effective treatment may tip the balance against transmission. This has been recognized 
for drug susceptible TB, and our data suggest the same for MDR-TB. Although further 
studies are needed to fully understand the mechanism for this remarkable effect, the 
implications of these observations are profound. Although many programs already treat 
tuberculosis in the community from the beginning, these data should reinforce the safety of 
that policy – as long as effective treatment can be assured by rapid molecular testing and 
treatment delivery assured by directly observed therapy. These data also suggest a refocused 
approach to TB transmission control in institutions and in the community, with an emphasis 
on active case finding by cough surveillance, rapid molecular diagnosis, and the prompt 
institution of fully supervised effective treatment, based on molecular DST. However, 
caution is warranted in putting these findings into practice. Effective, fully supervised 
treatment cannot be overemphasized, especially in areas where drug resistance is common. 
It would be a serious mistake to assume that treatment without rapid molecular confirmation 
of drug susceptibility or effective delivery is appropriate. Finally, it is likely that the current 
treatment of XDR-TB is often ineffective in rapidly interrupting transmission. Fortunately, 
one or more of the novel agents on the horizon may accomplish that goal.
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Table 2
Guinea pig infection rates in the five human-to-guinea pigs transmission studies. GP = guinea pig.
Experiment Number of patients Number of GPs Exposed Duration of GP exposure 
(months)
Proportion (and number) of infected 
GPs (control chamber only)
Pilot 26 360 4 74% (266)
Experiment 1 24 90 3 10% (9)
Experiment 2 15 90 2 54% (49)
Experiment 3 27 90 3 1% (1)
Experiment 4 17 90 3 77% (69)
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Table 3
Relative infectiousness of treated and untreated patients on Riley’s experimental ward, drug resistant and drug 
susceptible, relative to time spend on the ward (insert reference)
TB Patients Guinea Pigs Infected Relative Risk (adjusted for time on the ward)
Susceptible
 61 Untreated 29 100%
 29 Treated 1 2
Drug resistant
 6 Untreated 14 28
 11 Treated 6 5
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Table 4
Drug sensitivity of isolates from patients in the five human to guinea pig transmission experiments
Experiment Isolates with full DST (number of subjects) XDR isolates Transmission to Guinea Pigs (Proportion Infected)
Pilot 11 (26) 3 (MGIT) 74%
Experiment 1 10 (24) 5 (MGIT) 10%
Experiment 2 11 (15) 2 (MGIT) 54%
Experiment 3 21 (27) 0 (MGIT) 1%
Experiment 4 10 (17) 2 (MGIT) 77%
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